Safety Study of VCT-01™ in Split-Thickness Skin Graft Donor Site Wounds

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01292122
Recruitment Status : Terminated
First Posted : February 9, 2011
Last Update Posted : December 20, 2012
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to evaluate the safety of VCT-01 in split-thickness skin graft (STSG) donor site wounds and assess selected parameters of healing at the VCT-01-treated donor site.

Condition or disease Intervention/treatment Phase
Wounds Device: VCT-01 Not Applicable

Detailed Description:
An initial cohort of 5 subjects will be allocated to Group A. When all subjects enrolled in Group A have completed 14 days of post-treatment follow-up, results of donor site evaluations, histological analyses and reported adverse events will be reviewed by the Investigator and study Sponsor. If the data is suggestive of clinical benefit following treatment and absent any serious and/or unexpected adverse events, which are, in the opinion of the investigator, related to the treatment, the remaining subjects will be enrolled and randomized to Groups B, C or D.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 3 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single-Center, Prospective, Randomized Study of VCT-01™ in Split-Thickness Skin Graft Donor Site Wounds
Study Start Date : June 2011
Actual Primary Completion Date : September 2012
Actual Study Completion Date : September 2012

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: VCT-01-treated STSG donor site wound
Application of VCT-01 to STSG donor site wound at Day 0
Device: VCT-01
Application of bi-layered living cell-based product (VCT-01) to STSG donor site wound at Day 0

Primary Outcome Measures :
  1. Number of participants with Adverse Events and changes from Baseline Immunology at 1, 3, 6 and 12 Months [ Time Frame: Up to 12 months post-treatment ]
    Frequency and severity of reported adverse events and changes in results of immunology testing at Months 1, 3, 6 and 12 post-treatment as compared to baseline testing

Secondary Outcome Measures :
  1. Healing parameter [ Time Frame: Day 4 post-treatment ]
    Percentage area of questionable viability

  2. Healing parameter [ Time Frame: Day 14 post-treatment ]
    Percentage area of graft survival

  3. Healing parameter [ Time Frame: Up to 10 days post-treatment ]
    Histological and immunohistochemical analyses to examine cellular composition and tissue architecture.

  4. Healing parameter [ Time Frame: Up to 10 days post-treatment ]
    Microarray analysis to quantitatively measure molecular phenotypes expression.

  5. Healing parameter [ Time Frame: Up to 12 Months post-treatment ]
    Short tandem repeat analysis for persistence of VCT-01

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Subject is at least 18 years of age but no more than 55 years of age.
  2. Subject has a primary wound which requires treatment with a split-thickness skin graft; the graft cannot be harvested from a site from which a skin graft was previously obtained. If the primary wound is a result of a thermal or chemical burn, the total body surface area must be less than 15%.
  3. Females of childbearing potential must have a documented negative urine pregnancy test and must agree to use highly effective contraceptives for 6 months post-treatment.
  4. Subject has read, understood and signed a Health Research Ethics Board-approved Informed Consent Form.
  5. Subject is able and willing to comply with study procedures and instructions.

Exclusion Criteria:

  1. Female subjects who are pregnant or lactating.
  2. Clinically significant disease or condition that may compromise graft take and/or donor site healing (e.g. the presence of a bleeding disorder, capillary fragility, venous or arterial disorder directly affecting the donor site to be treated, known or suspected systemic malignancies, human immunodeficiency virus infection, renal or liver disease, uncontrolled diabetes mellitus, thrombocytopenia, vasculitis, poor nutritional status).
  3. Subjects who are currently receiving or have received within two months prior to treatment: systemic, inhaled or intranasal corticosteroids or immunosuppressant agents. Subjects receiving therapeutic doses of anticoagulants for pre-existing medical conditions (e.g. Plavix, Coumadin, Heparin, low molecular weight Heparin, non-steroidal anti-inflammatory drugs, herbal supplements), for whom a dose interruption from Screening through 2-Months post-treatment (pre-treatment / treatment / biopsy phase) is contraindicated, are excluded from the study.
  4. Any disorder (psychiatric, alcohol or substance abuse [within 12 months of treatment], physical disability) that might interfere with obtaining informed consent or the subject's ability to comply with study or protocol requirements, as determined by the Investigator.
  5. Subjects who have used any tobacco product within 3 months prior to treatment.
  6. Subjects previously treated with Apligraf®, Dermagraft or any other cell-based product, including autologous tissue at the treatment site.
  7. Subjects who have received an investigational drug, device or biological/bioactive treatment within 30 days prior to treatment (medical or dental).
  8. Subjects, who in the opinion of the Investigator, for any reason other than those listed above, will not be able to complete the study per protocol.
  9. Subjects, as determined by Screening immunology testing, that have specific antibodies to VCT-01 donor cell human leukocyte antigens.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01292122

Canada, Alberta
University of Alberta Hospital
Edmonton, Alberta, Canada, T6G 2B7
Sponsors and Collaborators
Principal Investigator: Edward E Tredget, MD University of Alberta

Responsible Party: Organogenesis Identifier: NCT01292122     History of Changes
Other Study ID Numbers: 10-GDS-001-VCT
First Posted: February 9, 2011    Key Record Dates
Last Update Posted: December 20, 2012
Last Verified: December 2012

Keywords provided by Organogenesis:
Wound Healing
Cell Therapy
Split-thickness skin graft donor site wound

Additional relevant MeSH terms:
Wounds and Injuries